China Resources Pharmaceutical Group (SEHK:3320) Stock Trades Cheap As Margin Recovery Seeks Credibility

China Resources Pharmaceutical Group stock closed at HK$4.65, capping a choppy few months in which the share price slipped over 5% in the past week and almost 1% over the past quarter. The market is still treating the company like a low-growth laggard with a P/E of about 6x, even as trailing net income from continuing operations reached ¥9.62b and net profit margin edged up to 1.5%.

For anyone looking beyond today’s tick-by-tick moves, this earnings release is really a story about valuation strain meeting improving profitability.

Love the low P/E and improving profitability at China Resources Pharmaceutical Group but worried it could still be a value trap? Compare it against our 270 high quality undervalued stocks for companies that pair modest valuations with stronger fundamentals.

H1 2026 Earnings Summary

• Revenue (H1 2026 vs H1 2025): ¥134,457.581m vs. ¥131,866.817m (steady top line with modest year on year growth)
• Net Income Excl. Extra Items (H1 2026 vs H1 2025): ¥2,186.632m vs. ¥2,073.328m (moderate year on year improvement in underlying profit)
• Basic EPS (H1 2026 vs H1 2025): Data for H1 2026 not disclosed vs. ¥0.330015 in H1 2025 (EPS trend for the latest half cannot be directly compared)
• Net Profit Margin TTM (H1 2026 vs H1 2025): 1.5% vs. 1.1% (margin higher over the trailing twelve months, indicating firmer profitability at China Resources Pharmaceutical Group)

Prefer clean, visual charts over wading through dense earnings tables and raw figures? You can view China Resources Pharmaceutical Group's valuation and profitability trends in an easy-to-read dashboard via our company report for China Resources Pharmaceutical Group.

China Resources Pharmaceutical: What Backs The Bullish View

For a constructive view on China Resources Pharmaceutical, the latest numbers give some support. Group revenue in H1 2026 was ¥134.5b against ¥131.9b a year earlier, which at least keeps the top line moving in the right direction. Net income excluding extra items rose to ¥2.19b from ¥2.07b. Trailing net profit margin improved to 1.5% from 1.1%. Tasly’s profit growth on flat to weaker sales also points to some margin discipline inside the portfolio, which fits the idea of a diversified, defensive healthcare platform gradually firming profitability.

China Resources Pharmaceutical: What Could Still Go Wrong

The same results also highlight why some investors stay cautious on China Resources Pharmaceutical. Subsidiary trends are uneven, with KPC Pharmaceuticals flagging a steep H1 2026 loss and CR Sanjiu reporting weaker profit and return on equity despite higher equity. That points to margin pressure and execution risk in parts of the group. The share price has also slipped over the past 7, 30 and 90 days, which suggests the market is not yet convinced that recent margin gains and Tasly’s contribution fully offset policy, cost and competitive headwinds.

Compare whether China Resources Pharmaceutical Group's tighter margins and low P/E are being treated as a genuine earnings reset or just dead money by the street. Track the consensus price target analysis for China Resources Pharmaceutical Group

Take Charge Of Your Next Move

If the mix of low P/E, modest revenue growth and improving margins at China Resources Pharmaceutical Group has you interested but cautious, register for free with Simply Wall St and add it to a Watchlist to watch how the share price trades against fair value and decide on your preferred entry point. Once you hold the stock, use the Portfolio Command Center to cut through market noise and focus on the key financial and valuation updates that matter most to your thesis. For a longer term view, tap into crowd insight and debate through the Community and see how other investors are interpreting the latest results. By spotting hidden catalysts and risks early, you give yourself a better chance of staying ahead of the market.

Seeking Fresh Alternatives Beyond China Resources Pharmaceutical?

Some stocks start to build quiet breakout momentum before most investors even notice. Use fresh screeners to spot ideas still under the radar for now and act now.

• Scan for resilient compounders with steady footing by checking the curated list of solid balance sheet and fundamentals stocks (427 results) while market attention is still elsewhere and pricing has not fully caught up.
• Catch early waves in powerful themes by reviewing 38 power grid technology and infrastructure stocks that could benefit if energy infrastructure spending keeps flying higher before the crowd fully tunes in.
• Target focused growth stories with real earnings by using 76 profitable AI stocks that aren't just burning cash to spot companies building momentum while results still matter and sentiment has not yet peaked.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com